Key points:
-
ExVentTM registered with Australia’s Therapeutic Goods Administration
-
Enables sale of the unique valve which is an accessory to Oventus’ O2Vent® oral therapeutic device for Obstructive Sleep Apnoea in Australia, Canada and a number of other jurisdictions, including Europe
-
ExVentTM expected to be made available in the US in late 2019, subject to FDA approval
-
Peer-reviewed clinical trials showed that when added to the O2Vent®, ExVentTM increased efficacy by 30% (refer to ASX announcement dated 13 June 2019)
-
The combination of O2Vent® with ExVentTM provided therapeutic outcomes comparable to CPAP for about 80% of patients while also offering a leap forward in patient adherence and comfort
Brisbane, Australia 20 June 2019: Oventus Medical Ltd or the Company (ASX: OVN) is pleased to announce that it has registered ExVentTM with Australia’s Therapeutic Goods Administration (TGA). This registration enables sales of the unique valve accessory which adds onto O2Vent devices and significantly increases efficacy rates of Oventus O2Vent oral airway management devices for moderate to severe Obstructive Sleep Apnoea (OSA) patients who require a high level of therapeutic intervention.
For further information please download the attached PDF:
Download this document
